跳至主要内容
临床试验/NCT03832959
NCT03832959Unknown不适用

Evaluation of Esophageal Damage During Conventional Pulmonary Vein Ablation Procedures and Potential Strategies to Protect the Esophagus. Pilot Study.

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2019年3月11日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
60
试验地点
2
主要终点
Severity of esophageal damage

研究概览

简要总结

Catheter ablation of atrial fibrillation with electrical isolation of the pulmonary veins in the left atrium carries risk of esophagus thermal lesion. EnsoETM is a device . This study evaluates the benefit of using the EnsoETM, a device device for esophageal temperature adjustments, during catheter ablation of atrial fibrillation. Half of participants will undergo esophageal temperature adjustment during pulmonary vein catheter ablation, while the other half will undergo catheter ablation with no esophageal temperature adjustment.

详细描述

  1. THEORETICAL FRAMEWORK. APPROACH TO THE PROBLEM

Background and justification

Atrial fibrillation is the most common type of heart arrhythmia. Electrical isolation of the pulmonary veins in the left atrium with ablation is standard therapy in the invasive treatment of atrial fibrillation. One of the risks of this intervention is thermal lesion of the esophagus, since it is in contact with the posterior wall of the left atrium. The energy applied for electrical isolation via either radiofrequency or cryotherapy can cause thermal lesions due to proximity with the esophagus and the vagus nerve/parasympathetic nervous system of the upper digestive tract. The incidence is not well established and data in the existing scarce publications show a very wide range, from 3 to 60%, according to the definition and means of the study used. The most recent systematic studies show values around 40-50%. The lesions observed vary in degree, from erythema or minor erosion to ulcers of the esophageal mucosa, including local hematomas, spasms, and esophageal/gastric motility disorders and even atrial-esophageal fistula, the extreme consequence of thermal esophageal lesion; the incidence of the latter is low (0.25%), but it has an elevated mortality. The best examination to diagnose and evaluate these lesions in all phases is upper digestive endoscopy or fibro esophagogastroscopy. Although it is routine in digestive services throughout the world, enabling the direct visualization and characterization of lesions, this technique is not performed systematically after ablation procedures, which explains the contradictory data in the literature.

Likewise, the possible long-term consequences of minor lesions are unknown, which, in a large number of patients are totally asymptomatic. For this reason, it cannot be ignored that acute tissue damage, however minimal, could lead to future changes in the form of late onset chronic esophageal pathology. The incidence and magnitude of esophageal involvement has been directly related to the ablation technique and protocol. Most available studies have been carried out in centers with ablation protocols that are significantly more aggressive than those used in our care facility. For this reason, the investigators do not have reliable data regarding the size of the problem in our center, which could present some differential characteristics.

To date, the prevention of these esophageal lesions has entailed: limits in the energy applied on the posterior wall of the left atrium (less power or shorter application time); monitoring of the luminal esophageal temperature during radio frequency or cryotherapy applications; stopping application early if certain temperatures considered risky were reached. However, the success of luminal esophageal temperature monitoring in preventing lesions varies widely, given that the temperature probes are very thin with respect to the total diameter of the esophagus, their position varies with respect to the cardiac tissue treated, and contact with the esophageal mucosa is inconstant. In fact, it has been reported that the temperature probes used for monitoring can contribute to increasing thermal lesions, given that their metal elements can boost direct heating/cooling of the tissue and make the lesion larger and last longer. In fact, the incidence of esophageal lesions is very similar, independent of the use of the temperature probe, or if it is a single or multi-sensor. Another controversial aspect of these temperature probes is that their use can lead to - at least potentially and in pursuit of safety - shorter, limited applications, which could cause incomplete non-transmural lesions and hamper the correct treatment of patients, thereby becoming a factor that increases the recurrence of atrial fibrillation. In addition, these probes should be deployed during the procedure so they are as close as possible to the application site (right or left veins depending on the time), which increases the procedure and fluoroscopy time, with consequent risks for both the patient and the medical team. All these limitations, together with significant economic cost overruns have meant that the use of this approach in our care facilities has been minimal and only for research purposes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients (older than 18 years of age) subjected to their first pulmonary vein isolation procedure with a catheter or balloon.

排除标准

  • Patients with known esophageal deformity or evidence of esophageal trauma (for example, history of esophagectomy, previous swallowing disorders, achalasia, etc.)
  • Patients with known ingestion of acidic or caustic poison in the previous 24 hours.
  • Patients weighing less than 40 kg.
  • Patients who know they are pregnant.
  • Patients under chronic daily treatment with an proton pump inhibitor or any gastrointestinal acid suppressant.
  • Patients under 18 years of age.
  • Patients who have not signed the informed consent form.

研究组 & 干预措施

Non esophageal protection

No Intervention

Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation to study esophageal lesions. The esophageal protection probe will not be used.

Esophageal protection

Experimental

Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation, using the esophageal protection probe EnsoETM

干预措施: EnsoETM (Device)

结局指标

主要结局

Severity of esophageal damage

时间窗: 1 day

Degree of esophageal lesions will be determined after ablation using esophagogastroscopy. Degree of esophageal lesions severity will be determined according to the Zargar endoscopy classification (0, I, IIa, IIb, IIIa, IIIb, IV)

Presence of esophageal damage

时间窗: <48 hours

Presence of esophageal lesions will be determined after ablation using magnetic resonance imaging

次要结局

  • Recurrence of atrial fibrillation(1 year)

研究者

发起方
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Esophageal Damage Protection During Pulmonary Vein... | 临床试验